A mutational approach to dissect the functional role of the putative CFTR “PTM-CODE”
- 1 April 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (5), 891-894
- https://doi.org/10.1016/j.jcf.2021.03.010
Abstract
No abstract availableKeywords
Funding Information
- Fondazione per la Ricerca sulla Fibrosi Cistica
This publication has 14 references indexed in Scilit:
- Deciphering the role of protein kinase CK2 in the maturation/stability of F508del-CFTRBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleThe New England Journal of Medicine, 2019
- Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growthScience Advances, 2019
- A posttranslational modification code for CFTR maturation is altered in cystic fibrosisScience Signaling, 2019
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesThe New England Journal of Medicine, 2018
- Molecular Structure of the Human CFTR Ion ChannelCell, 2017
- Regulatory Crosstalk by Protein Kinases on CFTR Trafficking and ActivityFrontiers in Chemistry, 2016
- CK2 Contribution to the Generation of the Human PhosphoproteomePublished by Wiley ,2013
- Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993